Haldol Decanoas

Haldol Decanoas is a European-market pharmaceutical product containing the active ingredient haloperidol decanoate, supplied as an intramuscular depot injection. It is a prescription‑only typical antipsychotic of the butyrophenone class, formulated for long‑acting delivery to support the management of psychotic disorders.

Haldol Decanoas is indicated for the treatment of schizophrenia and related psychotic conditions, particularly when a long‑acting injectable formulation is preferred. It may be used in acute psychotic episodes and as maintenance therapy for chronic psychosis.

- Schizophrenia in adults - Acute exacerbations of psychotic symptoms - Maintenance treatment to reduce relapse risk - Patients who have difficulty adhering to oral antipsychotics - Situations requiring a depot formulation for steady plasma levels

Side effects of haloperidol decanoate vary in frequency and severity. Common reactions are usually mild to moderate, while serious events are less frequent but require medical attention.

Common: - Drowsiness or sedation - Extrapyramidal symptoms such as tremor or rigidity - Dry mouth - Constipation - Weight gain - Elevated prolactin levels

Serious: - Neuroleptic malignant syndrome - Tardive dyskinesia - Severe hypotension - Cardiac arrhythmias (QT prolongation) - Severe allergic reactions (e.g., angioedema)

Before initiating Haldol Decanoas, clinicians should evaluate patient history and monitor for specific risks. Key precautions include:

- Assess for cardiovascular disease, especially QT prolongation risk - Screen for a personal or family history of movement disorders - Use cautiously in patients with hepatic or renal impairment - Monitor prolactin levels in long‑term therapy - Evaluate pregnancy and lactation status; benefits must outweigh potential risks - Conduct regular psychiatric assessments to gauge efficacy and side‑effect burden

Haloperidol decanoate can interact with several drug classes, affecting its safety profile or therapeutic effect.

Avoid: - Other dopamine antagonists or high‑potency antipsychotics (increased extrapyramidal risk) - Medications that prolong QT interval (e.g., certain antiarrhythmics, macrolide antibiotics) - Strong CYP3A4 inhibitors (may raise haloperidol levels)

Use with caution: - CYP3A4 inducers such as carbamazepine (may reduce efficacy) - CNS depressants, including benzodiazepines and alcohol (enhanced sedation) - Anticholinergic agents (may mask extrapyramidal symptoms) - Lithium (potential for neurotoxicity)